Expression of CD25 in Acute Myeloid Leukemia Is An Adverse Prognostic Factor Independent of the Chromosome Karyotype.

Yan-fang Liu; Li Dong; Chong Wang; Hui Sun; Qiu-tang Zhang; Meng Wang; Tao LI; Yan XU; Jie MA; Xin-sheng Xie; Ling Sun; Ding-ming Wan

Return

Expression of CD25 in Acute Myeloid Leukemia Is An Adverse Prognostic Factor Independent of the Chromosome Karyotype.

Author: Yan-Fang LIU ¹ ; Li DONG ² ; Chong WANG ² ; Hui SUN ² ; Qiu-Tang ZHANG ³ ; Meng WANG ² ; Tao LI ³ ; Yan XU ² ; Jie MA ² ; Xin-Sheng XIE ² ; Ling SUN ² ; Ding-Ming WAN ²
Author Information

1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail: liuyf371@163.com.
2. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
3. Institutes of Hematology of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Publication Type:Journal Article
MeSH: Bone Marrow; Humans; Interleukin-2 Receptor alpha Subunit; genetics; metabolism; Karyotype; Leukemia, Myeloid, Acute; genetics; metabolism; Prognosis; Remission Induction; Retrospective Studies
From: Journal of Experimental Hematology 2016;24(2):332-335
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo investigate the CD25 expression in patients with acute myeloid leukemia (AML) and its significance.
METHODSClinical data of 168 newly diagnosed AML patients (except APL) were collected. The expression of CD25 in AML patients and its clinical characteristics were retrospectively analyzed.
RESULTSThe leukemia cells of 29 out of 168 cases (17.26%) expressed CD25 antigen. Most of CD25 positive AML patients were occurred in patients with unfavourable or normal karyotype, higher WBC and Plt count at diagnosis and higher percentage of blasts in peripheral blood and bone marrow. Compared with CD25(-) AML patients, CD25(+) AML patients had lower CR rate (the CR rate of 1 course of treatment were 49.02% and 16.00%, respectively, P < 0.05, the CR rate of 2 courses of treatment were 74.60% and 46.67%, respectively, P < 0.05), and the OS time of CD25(+) AML patients were obviously shorter (P < 0.05). The OS in CD25(+) AML patients with unfavorable karyotype were not significantly different from that in patients with intermediate karyotype (P < 0.05).
CONCLUSIONThe CD25(+) AML patients have some typical clinical features, and the expression of CD25 in AML is an risk factor independent of the chromosome karyotype in terms of low complete remission rate and short survival time.